This Plain Language Summary of Publication article (PLSP) from Immunotherapy, covers Part B of the Phase 2 LILAC study, which evaluated litifilimab for moderate-to-severe cutaneous lupus erythematosus (CLE), with or without systemic lupus erythematosus (SLE). Published in 2022, the study compared three doses of litifilimab with a placebo to assess its effectiveness and safety.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus’ and was published in the New England Journal of Medicine.

Visit NEJM using the link to read the original article.